Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $118.89M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 2.43M
Average 2.92M
FATE EBITDA Margin
EBITDA as a percentage of revenue.
Fate Therapeutics, Inc.NASDAQ: FATE
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -2178.2%
EBITDA Margin was -2178.2% in Q1 FY2026, down 73.4 pp from a year earlier. On a trailing-twelve-month basis it was -1859.1%, down 709.8 pp year over year. Over 3 fiscal years it narrowed by 1633.0 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -1942.6% for the fiscal year ending Dec 2026, down from -1911.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -2178.2%-37.2 pp QoQ
- Last fiscal yearDec 2025
- -1911.2%-615.8 pp YoY
- LTMMar 2026
- -1859.1%-709.8 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1911.2%
- Year-over-year change
- -615.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1911.2% | -615.8pp |
| FY2024 | 2024-12-31 | -1295.4% | -1070.9pp |
| FY2023 | 2023-12-31 | -224.5% | +53.7pp |
| FY2022 | 2022-12-31 | -278.3% | +91.2pp |
| FY2021 | 2021-12-31 | -369.4% | — |
EBITDA Margin vs competitors
How FATE compares with its peers on the latest reported figures
- FATE's LTM Mar 2026 EBITDA Margin of -1859.1% is the 3rd highest of the 4 companies compared; the peer median is -632.1%.
- Its year-over-year change of -709.8 pp is the 3rd highest of 4, against a peer median of -502.0 pp.
- Over three fiscal years its change of -1633.0 pp compares with a peer median of -61663.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -455.3% | +1345.3 pp | — | |
| LTM Mar 2026 | -632.1% | -502.0 pp | -541.5 pp | |
| LTM Mar 2026 | -1859.1% | -709.8 pp | -1633.0 pp | |
| FY2025 | -125425.9% | -77690.7 pp | -122786.1 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding FATE) | -632.1% | -502.0 pp | -61663.8 pp | |
Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.85M | 96.3M | 63.53M | 13.63M | 6.65M |
| Cost of Revenue | 5.85M | 13.76M | 157.19M | 118.53M | 12.9M |
| Gross Profit | 50M | 82.54M | (93.65M) | (104.9M) | (6.26M) |
| Gross Margin | 89.5% | 85.7% | -147.4% | -769.6% | -94.1% |
| Research & Development | 215.52M | 320.45M | 172.6M | 135M | 107.83M |
| Selling, General & Admin | 57.32M | 84.23M | 96.86M | 90.64M | 46.52M |
| Operating Expenses | 266.99M | 390.93M | 96.86M | 105.38M | 141.45M |
| Depreciation & Amortization | 5.85M | 13.76M | 18.28M | 18.96M | 9.3M |
| EBITDA | (206.3M) | (267.96M) | (142.65M) | (176.58M) | (127.02M) |
| EBITDA Margin | -369.4% | -278.3% | -224.5% | -1295.4% | -1911.2% |
| Operating Income | (216.99M) | (308.39M) | (190.51M) | (210.28M) | (147.7M) |
| Operating Margin | -388.6% | -320.2% | -299.9% | -1542.6% | -2222.4% |
| Interest Income | 1.31M | 5.84M | 17.19M | 17.29M | 11.05M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.84M | 26.67M | 29.58M | 24.01M | 11.39M |
| Income Before Tax | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Pre-Tax Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Net Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| EPS (Basic) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| EPS (Diluted) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| Weighted Avg Shares | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
| Weighted Avg Shares (Diluted) | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
Fate Therapeutics, Inc.
NASDAQ:FATE
Intrinsic Alpha fair value
Locked
Current Price
$1.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.